Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. - Wikidata - wikimedia - TriplyDB

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.

http://www.wikidata.org/entity/Q46215271

about

Atypical hemolytic uremic syndrome Thrombotic microangiopathy with targeted cancer agents Cancer-associated thrombotic microangiopathy Drug-induced glomerular disease: direct cellular injury.Chronic VEGF blockade worsens glomerular injury in the remnant kidney model Antineoplastic agents and thrombotic microangiopathy.Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.A phase I study of sunitinib plus bevacizumab in advanced solid tumors.Thrombotic microangiopathies: multimers, metalloprotease, and beyond.Multifaceted hemolytic uremic syndrome in pediatrics.Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature.ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.Nephrotic Syndrome and Acute Renal Failure Apparently Induced by Sunitinib Bevacizumab increases risk for severe proteinuria in cancer patients.Anti-VEGF Cancer Therapy in Nephrology Practice Residual renal function after partial or radical nephrectomy for renal cell carcinoma.Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys Renal involvement in preeclampsia: similarities to VEGF ablation therapy Improvement in Gemcitabine-Induced Thrombotic Microangiopathy with Rituximab in a Patient with Ovarian Cancer: Mechanistic Considerations.The risk for anemia with targeted therapies for solid tumors Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.Vegfa protects the glomerular microvasculature in diabetes.Minimal change disease onset observed after bevacizumab administration.VEGF inhibition, hypertension, and renal toxicity Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling.New insights into molecular mechanisms of diabetic kidney disease.Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.Safety profile of new anticancer drugs.Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature.Inhibition of the VEGF signalling pathway and glomerular disorders.Onco-nephrology: current concepts and future perspectives.At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature.Sunitinib induced nephrotic syndrome and thrombotic microangiopathy.Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA.Adverse events of monoclonal antibodies used for cancer therapy.Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis.Sunitinib-Induced Acute Interstitial Nephritis in a Thrombocytopenic Renal Cell Cancer Patient.Pazopanib-induced Endothelial Injury with Podocyte Changes.Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib.All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.

P2860

Q21202864-51DD74B9-67FD-4CD0-918E-344789CE0164 Q24635904-EC646EF1-925F-4C79-B8D6-127A84C88AF0 Q26738984-6253EF62-F34B-4FAB-AA61-F4ECFBC02C87 Q27692666-5B6D17D7-56EE-4266-A7AB-018542816C5F Q28728129-8E0C6F85-834F-4DC3-908D-9DC909D867E8 Q30251919-A14A6623-3A63-49A2-9448-0D9E6A634CF7 Q30417015-DC4A630A-8D07-44B8-A19D-73CD1CBA094B Q33386345-C86CAF11-2CEC-4E8B-80DB-4C053E2EA764 Q33389435-F94094EC-876A-4AF6-8221-F2AC8D94A36A Q33405452-0FBDD5D6-3769-4009-8B60-07B2309E21F4 Q33418425-E1AC053D-7740-49D4-B4AB-1DC3129DAC60 Q33423350-3B4E001E-155B-474A-A116-3FE10DB88FC7 Q34038027-94EBCD3F-2EDC-4741-B76D-44ACE69F61A9 Q34124173-020D6B90-BE80-4AB9-AA58-CC1E5E7DCA43 Q34152125-07622700-C499-4E60-ACDD-8FD08EF966C2 Q34179292-06A64196-7012-4C00-B128-E28A4D01A933 Q34557530-125B4198-55B0-4139-AC0D-B7C0F5E1FD4C Q34735646-E6A79C7B-B2D5-4FC6-8336-A2B659E14B47 Q35901666-9B0F96A5-9869-410E-A5B5-87B8C7EF47DE Q35989994-48139974-F050-4368-BF80-41D4C2CB175C Q36150811-E718448D-6BDD-4EC3-92FF-3F9C7DFBAA83 Q36339615-5CC2D146-B443-4EF7-8066-BD28EE7BE95B Q36689167-60566C4F-B4D9-4BCC-A0A5-74882AD640EB Q37103555-C6BB81E3-E9A6-4021-8DAC-34706BD3F749 Q37416913-9FC3E5CC-F5CB-4D9F-B54B-412D3D252810 Q37598306-5BB82B47-181D-4948-8E23-0A670EC18743 Q37598818-1037749C-C5EE-4C33-A5D5-1BFB3C1E138C Q37696502-AB90955A-961E-453B-89A9-50DA80D80580 Q38169098-83C4EB0D-8922-471B-8206-A6FD676126D1 Q38284055-282F46CB-9AA3-4CE4-A9E1-2AA5F30610BB Q38382457-C1B1086E-D0AA-49BB-B3F6-6B918E12104E Q39309248-BCCEFA50-3F32-4F0D-846D-C4A4B512D3FC Q39712982-B7814AE3-70EB-4FAE-9E04-F733715FC3E9 Q40336593-AA471095-260B-4077-B51F-04ED99248F85 Q40812370-3976C524-0AA9-4170-BB12-57E7C22AD73E Q41612851-341FD52B-0CB5-4AD6-9DAF-62A8E17CC7D0 Q47649385-38723412-A481-459D-B730-DE03F5DD96A9 Q47672645-35B8016E-B25D-44BD-9A2D-5176557E9FC6 Q53239742-FD2BD2D3-E502-4A9B-8ECA-CA1BC63F9294 Q54494865-4FD13571-C173-406D-B9CD-B29FEB9DA81C

P2860

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.

http://www.wikidata.org/entity/Q46215271

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.

@en

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.

@nl

type

label

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.

@en

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.

@nl

prefLabel

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.

@en

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.

@nl

P1433

Q46215271-562D0856-D92F-44DC-B921-3E54284B552C

P1476

Q46215271-8A3902CD-3CEB-4109-81AE-840C48DB2FE7

P2093

Q46215271-561EC014-BEAA-47B2-892E-CA18E62BB272

Q46215271-5A769EEA-A6E3-4A02-A992-D1227B67FA8D

Q46215271-70680E6E-86D5-44F9-A8D1-3F4D8733D654

Q46215271-AB2225FF-2F5F-4819-8152-CAAD065F8629

Q46215271-AF22A558-D12B-48BD-BDC3-6C5909C84E5B

Q46215271-E38FF110-D538-4C7B-8854-E1626609A086

Q46215271-ED8E2D67-26F7-4AEA-B51E-95118AC2EEC4

P2860

Q46215271-02144E13-ABF2-43C2-9129-7AE80A8F27AD

Q46215271-1C4E0C18-23A0-4418-8345-AEA3DAAC0D1C

Q46215271-3E01C0B9-79FC-413A-8519-D0643725F45F

Q46215271-75C01DA1-12AB-45E9-B74D-1D404BE7E6AC

Q46215271-781E0487-07B4-4787-99E0-5C4771ED4751

Q46215271-A258F454-A24F-4D73-B2B6-A8A4A1F52480

Q46215271-A9BA4D01-D78B-4606-9E35-B189F44CCE53

Q46215271-C1C68947-22C6-4F60-BF16-81BB6065212F

Q46215271-CDB2DF24-633C-44B5-8A60-4E281239088E

P304

Q46215271-8B9F0856-29BC-4403-98E3-1571F408D7D5

P31

Q46215271-8314F3B1-834A-44BF-9588-238E5E1D02CE

P356

Q46215271-E3B31D18-7C35-4FCD-BDF6-FD34B3009098

P407

Q46215271-D93DDD9E-21A4-4ADD-AD14-AE3D6892F13B

P433

Q46215271-C2D9E3BF-BA8F-4C58-B3DB-FEC7D5C048ED

P478

Q46215271-8D566E4A-093E-45D1-8180-A65F75A615A5

P50

Q46215271-72D602C4-B85E-4C3B-9DAF-3CC821339735

Q46215271-73FAC091-8D9D-4640-B59D-CA298F689C8F

Q46215271-B5B76641-2C3E-4892-8203-9F552596FEF1

P577

Q46215271-45AE37C2-5D1D-4DA0-853C-305983086847

P5875

Q46215271-73AA2BBA-616B-478C-84E8-D1682C75DCC5

P698

Q46215271-9B3D8F07-4BA2-4AF2-A2B7-686D0A6E6C96

P356

P1433

Nephrology Dialysis Transplantation

P1476

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.

@en

P2093

Bertrand Knebelmann

http://www.w3.org/2001/XMLSchema#string

Caroline Robert

http://www.w3.org/2001/XMLSchema#string

Fadi Fakhouri

http://www.w3.org/2001/XMLSchema#string

Guillaume Bollée

http://www.w3.org/2001/XMLSchema#string

Géraldine Cazajous

http://www.w3.org/2001/XMLSchema#string

Laure-Hélène Noël

http://www.w3.org/2001/XMLSchema#string

Natacha Patey

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibition and renal thrombotic microangiopathy

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects.

Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.

The role of vascular endothelial growth factor (VEGF) in renal pathophysiology.

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.

Circulating angiogenic factors and the risk of preeclampsia.

P304

682-685

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFN657

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Patrick Bruneval

Caroline Robert

Jean-Michel Goujon

P577

2008-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23569742

http://www.w3.org/2001/XMLSchema#string

P698

19054798

http://www.w3.org/2001/XMLSchema#string